Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 66.3% in the second quarter, Holdings Channel.com reports. The fund owned 27,316 shares of the company’s stock after selling 53,631 shares during the quarter. Amalgamated Bank’s holdings in Elanco Animal Health were worth $394,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Hunter Associates Investment Management LLC lifted its holdings in shares of Elanco Animal Health by 5.1% in the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock valued at $269,000 after purchasing an additional 800 shares in the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of Elanco Animal Health by 3.6% in the second quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after purchasing an additional 893 shares in the last quarter. HBK Sorce Advisory LLC lifted its holdings in shares of Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after purchasing an additional 1,107 shares in the last quarter. Atomi Financial Group Inc. lifted its holdings in shares of Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock valued at $177,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Resonant Capital Advisors LLC lifted its holdings in shares of Elanco Animal Health by 5.0% in the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company’s stock valued at $394,000 after purchasing an additional 1,306 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 4.3 %

Shares of ELAN opened at $14.32 on Monday. Elanco Animal Health Incorporated has a 12-month low of $8.52 and a 12-month high of $18.80. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $7.08 billion, a price-to-earnings ratio of -5.40, a P/E/G ratio of 1.33 and a beta of 1.40. The stock’s 50-day moving average price is $14.05 and its 200 day moving average price is $15.07.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.18 earnings per share. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Piper Sandler cut their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, July 1st. Finally, Barclays increased their price objective on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of “Hold” and a consensus target price of $17.43.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at approximately $1,886,450. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the purchase, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.